THERAPEUTIC PERSPECTIVES IN ACTINIC AND OTHER KERATOSES
1996; Wiley; Volume: 35; Issue: 8 Linguagem: Inglês
10.1111/j.1365-4362.1996.tb03649.x
ISSN1365-4632
Autores Tópico(s)Genetic and rare skin diseases.
ResumoInternational Journal of DermatologyVolume 35, Issue 8 p. 533-538 THERAPEUTIC PERSPECTIVES IN ACTINIC AND OTHER KERATOSES ROBERT A. SCHWARTZ M.D., MPH, Corresponding Author ROBERT A. SCHWARTZ M.D., MPH Department of Dermatology and Preventive Medicine and Community Health, New Jersey Medical School, Newark, New JerseyAddress for correspondence: R.A. Schwartz, M.D., Dermatology, New Jersey Medical School, 185 South Orange Avenue, Newark, NJ 07103–2714.Search for more papers by this author ROBERT A. SCHWARTZ M.D., MPH, Corresponding Author ROBERT A. SCHWARTZ M.D., MPH Department of Dermatology and Preventive Medicine and Community Health, New Jersey Medical School, Newark, New JerseyAddress for correspondence: R.A. Schwartz, M.D., Dermatology, New Jersey Medical School, 185 South Orange Avenue, Newark, NJ 07103–2714.Search for more papers by this author First published: August 1996 https://doi.org/10.1111/j.1365-4362.1996.tb03649.xCitations: 15AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 Schwartz RA. Skin cancer recognition and management. New York : Springer-Verlag, 1988: 4– 56. 2 Schwartz RA, Stoll HL Jr. Epithelial neoplasms and precancerous lesions. In: TB Fitzpatrick, AZ Eisen, K Wolff, et al., eds. Dermatology in general medicine. 4th Ed. New York : McGraw-Hill, 1993: 804– 821. 3 Unna PG. Die Histopathologie der Hautkrankheiten. Berlin : August Hirschwald Verlag, 1894: 719– 724. 4 Dubreuilh W. Des hyperkeratoses circonscrites. In: JJ Pringle, ed. Third International Congress of Dermatology. London, August 4th to 8th, 1896. Official Transactions, London : Waterlow and Sons, 1898: 125– 176. 5 Unna PG. Über das Wesen der normalen und pathologischen Verhornung. In: JJ Pringle, ed. Third International Congress of Dermatology. London, August 4th to 8th, 1896. Official Transactions, London : Waterlow and Sons, 1898: 95– 118. 6 Schwartz RA. Premalignant keratinocytic neoplasms. J Am Acad Dermatol. (In press). 7 Duhreuilh W. Épithéliotnatose d'origine solaire. Ann Dermatol Syphiligr 1907; 38: 387– 416. 8 Engman MF. Precancerous conditions of the skin. J Lab Clin Med 1915; 1: 31– 39. 9 Darier J. A text-book of dermatology. Authorized translation from the second French edition edited with notes by S. Pollitzer. Philadelphia : Lea & Febinger, 1920: 209– 210. 10 McCoy JN. Solar keratoses and cutaneous cancer. Arch Dermatol Syphilol 1920; 1: 175– 181. 11 Freudenthal W. Verruca senilis und Keratoma senile. Arch f Dermatol u Syph (Berlin) 1926; 152: 505– 528. 12 Freudenthal W. Rumpfhautepidieliom (nebst Remerkungen über die Verruca senilis und das Keratoma senile. Arch f Dermatol u Syph (Berlin) 1929; 158: 539– 544. 13 Hookey JA. Keratoma senilis and verruca senilis. A clinical and histopathologic study. Arch Dermatol Syphilol 1931; 23: 946– 959. 14 Bloch B. Cancers and precancerous affections from the dermatological viewpoint. Cancer Rev 1932; 7: 65– 98. 15 Montgomery H, Dörffel J. Verruca senilis und Keratoma senile. Arch f Dermatol u Syph (Berlin) 1932; 166: 286– 296. 16 MacKee GM, Cipollaro AC. Cutaneous cancer and pre-cancer. A practical monograph. New York : Am J Cancer, 1937: 4– 99. 17 Montgomery H. Precancerous dermatosis and epithelioma in situ. Arch Dermatol Syphilol 1939; 39: 387– 408. 18 Frost CA, Green AC. Epidemiology of solar keratoses. Br J Dermatol 1994; 131: 455– 464. 19 Bendl BJ, Graham JH. New concepts on the origin of squamous cell carcinomas of the skin: solar (senile) keratosis with squamous cell carcinoma—a clinicopathologic and histochemical study. In: 6th National Cancer Conference Proceedings. Philadelphia : JB Lippincott, 1970: 471– 488. 20 Lambert WC, Schwartz RA. Evidence for origin of basal cell carcinomas in solar (actinic) keratoses. J Cutan Pathol 1988; 15: 322. [Abstr]. 21 Hurwitz RM, Monger LE. Solar keratosis: an evolving squamous cell carcinoma. Benign or malignant Dermatol Surg 1995; 21: 184. (Letter). 22 Marks R, Foley P, Goodman G, et al. Spontaneous remission of solar keratoses: the case for conservative management. Br J Dermatol 1986; 115: 649– 655. 23 Mostow EN, Johnson TM. Malignant transformation from actinic keratoses to squamous cell carcinoma. Arch Dermatol 1992; 128: 560– 561. (Letter). 24 Dodson JM, DeSpain J, Hewett JE, et al. Malignant potential of actinic keratoses and the controversy over treatment. A patient-oriented perspective. Arch Dermatol 1991; 127: 1029– 1031. 25 Marks R. The role of treatment of actinic keratoses in the prevention of morbidity and mortality due to squamous cell carcinoma. Arch Dermatol 1991; 127: 1031– 1033. 26 Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet 1988; 1: 795– 796. 27 Fukamizu H, Inoue K, Matsumoto K, et al. Metastatic squamous-cell carcinomas derived from solar keratosis. J Dermatol Surg Oncol 1985; 11: 518– 522. 28 Lund HZ. How often does squamous cell carcinoma of skin metastasize. Arch Dermatol 1965; 92: 635– 637. 29 Graham JH. Selected precancerous skin and mucocutaneous lesions. In: Neoplasms of skin and malignant melanoma. Chicago : Year Book Medical Publishers, 1976: 69– 121. 30 Pinkus H. Actinic keratosis—actinic skin. In: R Andrade, SL Gumport, GL Popkin, et al., eds. Cancer of the skin biology-diagnosis-management. Philadelphia : WB Saunders, 1976: 437– 457. 31 Marks R. Solar keratoses. Br J Dermatol 1990; 122 (Suppl 35): 49– 60. 32 Drake LA, Ceilley RI, Cornelison RL, et al. Guidelines of care for actinic keratoses. J Am Acad Dermatol 1995; 32: 95– 98. 33 Falkson G, Schulz EJ. Skin changes in patients treated with 5–fluorouracil. Br J Dermatol 1962; 74: 229– 236. 34 Launde J, Henschke CI, Mohammed N. The Tanzanian human albino skin. Natural history. Cancer 1985; 55: 1823– 1828. 35 Picascia DD, Robinson JK. Actinic cheilitis: a review of the etiology, differential diagnosis, and treatment. J Am Acad Dermatol 1987; 17: 255– 264. 36 Umbert P, Sanchez-Pegafia M, Salleras M. Actinic keratosis with follicular invasion. J Cutan Pathol 1995; 22: 76. [Abstr]. 37 Thianprasit M. Chronic cutaneous arsenism treated with aromatic retinoid. J Med Assoc Thailand 1984; 67: 93– 100. 38 Jackson R, Laughlin S. Historical survey of methods of treatment of skin cancer. In: RA Schwartz, ed. Skin cancer recognition and management. New York : Springer-Verlag, 1988: 276– 291. 39 Klein E, Milgrom H, Helm F. Tumors of the skin. I. Effects of local use of cytostatic agents. Skin 1962; 1: 81– 87. 40 Burgess GH, Bloch A, Stoll H, et al. Effect of topical tubercidin on basal cell carcinomas and actinic keratoses. Cancer 1974; 34: 250– 253. 41 Klein E. Tumors of the skin. X. Immunotherapy of cutaneous and mucosal neoplasms. NY State J Med 1968; 68: 900– 911. 42 Klein E. Tumors of skin. IX. Local cytostatic therapy of cutaneous and mucosal premalignant and malignant lesions. NY State J Med 1968; 68: 886– 899. 43 Belisario JC. Ten years' experience with topical cytotoxic therapy for cutaneous cancer and precancer-type and number of lesions treated (Part I). Cutis 1970; 6: 293– 306. 44 Belisario JC. Ten years' experience with topical cytotoxic therapy for cutaneous cancer and precancer-type and number of lesions treated (Part II). Cutis 1970; 6: 401– 412. 45 Klein E, Stoll HL Jr, Milgrom H, et al. Tumors of skin. XII. Topical 5–fluorouracil for epidermal neoplasms. J Surg Oncol 1971; 3: 331– 350. 46 Klein E, Schwartz RA. Cancer and the skin. In: JF Holland, E Frei, eds. Cancer medicine. 2nd Ed. Philadelphia : Lea & Febiger, 1982: 2057– 2108. 47 Klein E, Schwartz RA, Case RW, et al. Accessible tumors. In: AF LoBuglio, ed. Clinical immunotherapy. New York : Marcel Dekker, 1980: 31– 71. 48 Dabski K, Helm F. Immunotherapy. In: RA Schwartz, ed. Skin cancer recognition and management. New York : Springer-Verlag, 1988: 363– 377. 49 Eaglstein WH, Weinstein GD, Frost P. Fluorouracil: mechanism of action in human skin and actinic keratoses. I. Effect on DNA synthesis in vivo.. Arch Dermatol 1970; 101: 132– 139. 50 Robinson TA, Kligman AM. Treatment of solar keratoses of the extremities with retinoic acid and 5–fluorouracil. Br J Dermatol 1975; 92: 703– 706. 51 Bercovitch L. Topical chemotherapy of actinic keratoses of the upper extremities with tretinoin and 5-fluorouracil: a double-blinded controlled study. Br J Dermatol 1987; 116: 549– 552. 52 Breza T, Taylor JR, Eaglstein WH. Noninflammatory destruction of actinic keratoses by fluorouracil. Arch Dermatol 1976; 112: 1256– 1258. 53 Klein E, Stoll HL, Miller E, et al. The effects of 5-fluorouracil (5–FU) ointment in the treatment of neoplastic dermatoses. Dermatologica 1970; 140(Suppl 1): 21– 33. 54 Lawrence N, Cox SE, Cockerell CJ, et al. A comparison of the efficacy and safety of Jessner's solution and 35% trichloroacetic acid vs. 5% fluorouracil in the treatment of widespread facial actinic keratoses. Arch Dermatol 1995; 131: 176– 181. 55 Dzubow LM. Treatment of actinic keratoses. “Life in the fast lane. Dermatol Surg 1995; 21: 121. 56 Unis ME. Short-term intensive 5-fluorouracil treatment of actinic keratoses. Dermatol Surg 1995; 21: 162– 163. 57 Pearlman DL. Weekly pulse dosing: effective and comfortable topical 5-fluorouracil treatment of multiple facial actinic keratoses. J Am Acad Dermatol 1991; 25: 665– 667. 58 Griffin TD, Van Scott EJ. Use of pyruvic acid in the treatment of actinic keratoses: a clinical and histopathologic study. Cutis 1991; 47: 325– 329. 59 Goldman L. The response of skin cancer to topical therapy with 5-fluorouracil. Cancer Chemother Reports 1963; 28: 49– 52. 60 Abadir DM. Combination of topical 5-fluorouracil with cryotherapy for treatment of actinic keratoses. J Dermatol Surg Oncol 1983; 9: 403– 404. 61 Field LM. Dermabrasion vs. 5-FU for actinic damage. J Am Acad Dermatol 1982; 6: 269– 270. (Letter). 62 Dillaha CJ, Jansen GT, Honeycutt WM, et al. Selective cytotoxic effect of topical 5-fluorouracil. Arch Dermatol 1963; 88: 247– 256. 63 Dillaha CJ, Jansen GT, Honeycutt WM, et al. Further studies with topical 5-fluorouracil. Arch Dermatol 1965; 92: 410– 417. 64 Dabski K, Helm F. Topical chemotherapy. In: RA Schwartz, ed. Skin cancer recognition and management. New York : Springer-Verlag, 1988: 378– 389. 65 Simmonds WL. Double-blind investigation comparing a 1%-vs-5% 5-fluorouracil topical cream in patients with multiple actinic keratoses. Cutis 1973; 12: 615– 617. 66 Belisario JC. Topical cytotoxic therapy for cutaneous cancer and pre-cancer. Arch Dermatol 1965; 92: 293– 303. 67 Sams WM. Untoward response with topical fluorouracil. Arch Dermatol 1968; 97: 14– 19. 68 de Berker D, Marren P, Powell SM, et al. Contact sensitivity to the stearyl alcohol in Efudix cream (5-fluorouracil). Contact Dermatitis 1992; 26: 138. 69 Epstein E. Warning! Masoprocol is a potent sensitizer. J Am Acad Dermatol 1994; 31: 295– 296. (Letter). 70 Olsen EA, Abernethy ML, Kulp-Shorten C, et al. A double-blind, vehicle-controlled study evaluating masoprocol cream in the treatment of actinic keratoses on the head and neck. J Am Acad Dermatol 1991; 24: 738– 743. 71 Kulp-Shorten C, Konnikov N, Callen J. Comparative, evaluation of the efficacy and safety of masoprocol and 5-fluorouracil cream for the treatment of multiple actinic keratoses of the head and neck. J Geriatr Dermatol 1993; 1: 161– 168. 72 Olsen EA, Abernethy ML, Kulp-Shorten C, et al. Reply to Epstein E: Warning! Masoprocol is a potent sensitizer. J Am Acad Dermatol 1994; 31: 296– 297. (Letter). 73 Brown RJ. A comparative evaluation of masoprocol vs. 5-fluorouracil for the treatment of actinic keratoses. J Invest Dermatol 1995; 104: 694. [Abstr]. 74 Cham BE, Daunter B, Evans RA. Topical treatment of malignant and premalignant skin lesions by very low concentrations of a standard mixture (BEC) of solasodine glycosides. Cancer Lett 1991; 59: 183– 192. 75 Cham BE. Solasodine glycosides as anticancer agents: preclinical and clinical studies. Asia Pacific J Pharmacol 1994; 9: 113– 118. 76 Strzelczyk M, Dubieniecki W, Rutkowski M, et al. New original preparations antineoplastic (skin cancers)—Sulficyd—antiexudative and antiinflaminatory—ulcer CLEPS. In: H Szarmach, ed. Advances in pathogenesis, diagnosis and treatment of skin and venereal diseases. Proceedings of the 24th Congress of the Polish Dermatologic Society, Gdańsk, Poland, September 24–26, 1992. Gdańsk : Drukamia Archidiecezji Gdańskiej, 1992: 790– 795. 77 Jackson R, Laughlin S. Electrodesiccation and curettage. In: RA Schwartz, ed. Skin cancer recognition and management. New York : Springer-Verlag, 1988: 292– 295. 78 Kuflik EG. Cryosurgery updated. J Am Acad Dermatol 1994; 31: 925– 944. 79 Kaszuba A, Wiacek S, Trznaldel-Budźko E, et al. Krioterapia pòdtlenkiem azotu (N2O) w praktyce dennatologicznej. Przegl Dermatol 1995; 82: 547– 554. 80 Kaźmierowski M, Bowszyc J. Dermatologiczne wskazania do krioterapii płynnym azotem i podtlenkiem azotu ze szczególnym uwzglȩ, dnieniem nowotworów skóry. Przegl Dermatol 1985; 72: 330– 338. 81 Lubritz RR, Smolewski SA. Cryosurgery cure rate of premalignant leukoplakia of the lower lip. J Dermatol Surg Oncol 1983; 9: 235– 237. 82 Lubritz RR, Smolewski SA. Cryosurgery cure rate of actinic keratoses. J Am Acad Dermatol 1982; 7: 631– 632. 83 Kuflik EG, Kuflik AS. Cryosurgery. In: DJ Demis, ed. Clinical dermatology. 20th Ed. Philadelphia : JB Lippincott, 1993:Unit 37–5: 1– 5. 84 Drake LA, Ceilley RI, Cornelison RL, et al. Guidelines of care for Cryosurgery. J Am Acad Dermatol 1994; 31: 648– 653. 85 Crutcher WA. Cryosurgery of cutaneous malignancies: In: RA Schwartz. Skin cancer recognition and management. New York : Springer-Verlag, 1988: 299– 310. 86 Holt PJA. Cryotherapy for skin cancer: results of a 5–year period using liquid nitrogen spray Cryosurgery. Br J Dermatol 1988; 119: 231– 240. 87 Chiarello SE. Full-face cryo- (liquid nitrogen) peel. J Dermatol Surg Oncol 1992; 18: 329– 332. 88 Placek W, Jasiel E, Czubek M, et al. Thermoelectric Cryosurgery in dermatology. In: A Omulecki, ed. Congressus Dermatologiae 23–25.06.1995. Łódź. Streszczenie referatów. Warsaw , Poland : SB Publications, 1995: 212. [Abstr]. 89 Edwards L, Levine N, Smiles KA. The effect of topical interferon alpha2b on actinic keratoses. J Dermatol Surg Oncol 1990; 16: 446– 449. 90 Shuttleworth D, Marks R. A comparison of the effects of intralesional interferon α-2b and topical 5% 5-fluorouracil cream in the treatment of solar keratoses and Bowen's disease. J Dermatol Treat 1989; 1: 65– 68. 91 Eckert RL, Agarwal C, Hembree JR, et al. Retinoids, interferon, human papillomavirus, and cancer. In: H. Mukhtar, ed. Skin cancer: mechanisms and human relevance. Boca Raton , CRC Press, 1995: 361– 370. 92 Helm F, Klein E, Rivera EP. Studies on local administration of 2,3,5-tri-ethylene-imino-(1,4)-benzoquinone (trenimon) on epitheliomas and keratoses. J Invest Dermatol 1965; 45: 152– 159. 93 Peck GL. Topical tretinoin in actinic keratosis and basal cell carcinoma. J Am Acad Dermatol 1986; 15: 829– 835. 94 Goldfarb MT, Ellis CN, Voorhees JJ. Topical tretinoin: its use in daily practice to reverse photoageing. Br J Dermatol 1990; 122(Suppl 35): 87– 91. 95 Noszczyk M, Majeski S. Mechanizmy starzenia sie skóry oraz zapobiegawcze działanie retinoidów. Przegl Dermatol 1993; 80: 441– 446. 96 Rogoziński T, Geiger J-M, Czarnetzki BM, et al. Acitretin in the treatment and prevention of viral, premalignant and malignant skin lesions. J Dermatol Treat 1989; 1: 91– 93. 97 Meyskens FL Jr. Coming of age—the chemoprevention of cancer. N Engl J Med 1990; 323: 825– 827. 98 Misiewicz J, Sendagorta E, Golebiowska A, et al. Topical treatment of multiple actinic keratoses of the face with arotinoid methyl sulfone (Ro 14-9706) cream versus tretinoin cream: a double-blind, comparative study. J Am Acad Dermatol 1991; 24: 448– 451. 99 Alirezai M, Dupuy P, Amblard P, et al. Clinical evaluation of topical isotretinoin in the treatment of actinic keratosis. J Am Acad Dermatol 1994; 30: 447– 451. 100 Moriarty M, Dunn J, Darragh A, et al. Etretinate in treatment of actinic keratosis. A double-blind crossover study. Lancet 1982; i: 364– 365. 101 Hughes BR, Marks R, Pearse AD, et al. Clinical response and tissue effects of etretinate treatment of patients with solar keratoses and basal cell carcinoma. J Am Acad Dermatol 1988; 18: 522– 529. 102 Kaźmierowski M. Retinoidy w leczeniu raków i chłloniaków skóry. Postepy Dermatol 1993; 10: 137– 143. 103 Chen L-C, De Luca LM. Retinoid effects on skin cancer. In: H Mukhtar, ed. Skin cancer: mechanisms and human relevance. Boca Raton : CRC Press, 1995: 401– 424. 104 Stüttgen G. Zur Lokalbehandlung von Keratosen mit Vitamin-A-Säure. Dermatologica (Basel) 1962; 124: 65– 80. 105 Majewski S, Skopinska M, Bollag W, et al. Combination of isotretinoin and calcitriol for precancerous and cancerous skin lesions. Lancet 1994; 344: 1510– 1511. (Letter). 106 Skopinska M, Majewski S, Bollag W, et al. Synergistic effect of retinoids and vitamin D3 in the treatment of precancerous lesions and skin cancers. In: A Omulecki, ed. Congressus Dermatologiae 23–25.06.1995. Łódź. Streszczenie referatów. Warsaw , Poland : SB Publications, 1995: 44. [Abstr]. 107 Noszczyk M, Majewski S, Rudnicka L, et al. The mechanisms of action of retinoids in the treatment of photoaged skin. In: A Omulecki, ed. Congressus Dermatologiae 23-25.06.1995. Łódź. Streszczenie referatów. Warsaw , Poland : SB Publications, 1995: 72. [Abstr]. 108 Hevia O, Nemeth AJ, Taylor JR. Tretinoin accelerates healing after trichloroacetic acid chemical peel. Arch Dermatol 1991; 127: 678– 682. 109 Verma AK. Protein kinase C and skin cancer prevention. In: A Mukhtar, ed. Skin cancer: mechanisms and human relevance. Boca Raton : CRC Press, 1995: 383– 390. 110 Agarwal R, Katiyar SK, Mukhtar H. Skin cancer chemoprevention by naturally occurring polyphenols. In: H Mukhtar, ed. Skin cancer: mechanisms and human relevance. Boca Raton : CRC Press, 1995: 391– 399. 111 Zelickson BD, Roenigk RK. Actinic cheilitis. Treatment with the carbon dioxide laser. Cancer 1990; 65: 1307– 1311. 112 Spicer MS, Goldberg DJ. Lasers in dermatology. J Am Acad Dermatol 1996; 34: 1– 25. 113 Fitzpatrick RE. Use of the ultrapulse CO2 laser for dermatology including facial resurfacing. Lasers Surg Med 1995; 15(Suppl 7): 50. [Abstr]. 114 Sidorowicz W. Zastosowanie lasera argonowego w leczeniu wybanych zmian skórnych. In: H Szarmach, ed. Advances in pathogenesis, diagnosis, and treatment of skin and venereal diseases. Proceedings of the 24th Congress of the Polish Dermatologic Society Gdansk. September 24–26, 1992. Gdańsk : Drukamia Archidiecezji Gdańskiej, 1992: 860– 864. 115 Rubisz-Brzezinska J, Brzezińska-Weisło L. Przydatność lasera wysokoenergetycznego Nd: YAG w terapii nabłoniaków podstnownokomórkowych skóry i niektórych stanów przednowotworowych. Przegl Dermatol 1993; 80: 469– 474. 116 Szeimies RM, Karrer S, Sauerwald A, et al. Photodynamic therapy with topical application of 5-aminolevulinic acid in the treatment of actinic keratoses: an initial clinical study. Dermatology (Basel) 1996; 192: 246– 251. 117 Szeimies R-M, Karrer S, Heine A, Saucrwiad A, et al. Arsenic-induced skin tumors treated with topical photodynamic therapy after application of 5-aminolevulinic acid. Eur J Dermatol 1995; 5: 208– 211. 118 Winton GB, Salasche SJ. Dermabrasion of the scalp as a treatment for actinic damage. J Am Acad Dermatol 1986; 14: 661– 668. 119 Nelson BR, Fader DJ, Gillard M, et al. The role of dermabrasion and chemical peels in the treatment of patients with xeroderma pigmentosum. J Am Acad Dermatol 1995; 32: 623– 626. 120 Swinehart JM. Salicylic acid ointment peeling of the hands and forearms. Effective nonsurgical removal of pigmented lesions and actinic damage. J Dermatol Surg Oncol 1992; 18: 495– 498. 121 Ditre CM, Griffin TD, Murphy GF, et al. The effects of alpha hydroxyacids (AHAs) on photoaged skin: a pilot clinical, histological and ultrastructural study. J Invest Dermatol 1995; 104: 690. [Abstr]. 122 Stuzin JM, Baker TJ, Gordon HL. Treatment of photo-aging. Facial chemical peeling (phenol and trichloroacetic acid) and dermabrasion. Clinics Plastic Surg 1993; 20: 9– 25. 123 Goh SH. The treatment of visible signs of senescence: the Asian experience. Br J Dermatol 1990; 122(Suppl 35): 105– 109. 124 van Zuuren EJ, Posma AN, Scholtens REM, et al. Resurfacing the back of the hand as treatment and prevention of multiple skin cancers in kidney transplant recipients. J Am Acad Dermatol 1994; 31: 760– 764. Citing Literature Volume35, Issue8August 1996Pages 533-538 ReferencesRelatedInformation
Referência(s)